VC  Devon Park Bioventures

     Office Locations:

1400 Liberty Ridge Drive, Suite 103
Wayne, PA 19087
Phone: 484-320-4900
Fax: 484-320-4920



  • Early



  • Life Sciences & Healthcare
  • Medical Device



    Devon Park Bioventures is a venture capital fund targeting investments in therapeutics companies and, in certain cases, medical device, diagnostic and drug discovery technology companies. The firm was spun off from TL Ventures in 2006 and closed a $55 million fund. Devon Park focuses primarily on companies that are actively developing compounds that will be advanced through clinical trials prior to being marketed as FDA approved drugs. Devon Park will also invest in medical device, diagnostic or drug discovery technology companies if they believe that the companies being considered are developing products and/or technologies with the potential to produce a transformation in the way in which a disease is treated or diagnosed or drugs are developed.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Christopher Moller Ph.D. General Partner
    Devang Kantesaria M.D. General Partner
    Marc Ostro Ph.D. General Partner


    Portfolio companies include:

      Cara Therapeutics
        web link

      Cardeas Pharmaceuticals
        web link

      Cempra Pharmaceuticals
        web link

      Diasome Pharmaceuticals
        web link

      Inotek Pharmaceuticals
        web link

      MicuRx Pharmaceuticals
        web link

      Proteon Therapeutics
        web link

      Sopherion Therapeutics
        web link

      Vascular Magnetics
        web link

      ZS Pharma
        web link


    Recent News: